Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 5/20 | 0.35 |
| ▸ | PPARD | Q03181 | 5/20 | 0.35 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.32 |
| ▸ | HMOX1 | P09601 | 2/20 | 0.32 |
| ▸ | CCNT1 | O60563 | 3/20 | 0.31 |
| ▸ | CDK9 | P50750 | 3/20 | 0.31 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.31 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.31 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.30 |
| ▸ | RORC | P51449 | 1/20 | 0.30 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15381777 | 0.95 | PARP10 (0.34) | FFAR1PPARDFFAR4CCNT1CDK9 | |
| SCHEMBL11933341 | 0.94 | FFAR1 (0.34) | FFAR1PPARDFFAR4HMOX1CCNT1 | |
| SCHEMBL11933342 | 0.94 | FFAR1 (0.34) | FFAR1PPARDFFAR4HMOX1CCNT1 | |
| SCHEMBL15381740 | 0.90 | CRBN (0.32) | FFAR1PPARDFFAR4HMOX1PARP10 | |
| SCHEMBL11933336 | 0.90 | CCNT1 (0.32) | CCNT1CDK9 | |
| SCHEMBL11933191 | 0.90 | CCNT1 (0.32) | CCNT1CDK9 | |
| SCHEMBL11933194 | 0.87 | PDE5A (0.35) | FFAR4CCNT1CDK9 | |
| SCHEMBL11939257 | 0.87 | FFAR4 (0.35) | FFAR1PPARDFFAR4CCNT1CDK9 | |
| SCHEMBL11933198 | 0.85 | FFAR4 (0.33) | FFAR1PPARDFFAR4CCNT1CDK9 | |
| SCHEMBL10302440 | 0.85 | THRA (0.34) | FFAR1PPARDFFAR4CCNT1CDK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8580147-B2 | Liquid crystal compound, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2013-11-12 | — | — | US | disclosed |
| US-20120168677-A1 | LIQUID CRYSTAL COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC PETROCHEMICAL CORPORATION (JP) | 2012-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120168677-A1 | LIQUID CRYSTAL COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | CXCR1, OCIAD1, LEO1 | FFAR1 113/4885PPARD 1968/4885FFAR4 1038/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.